Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin D. Dieckhaus has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infectious Diseases, Antimicrobial Resistance, and Diagnostic Stewardship Among Sex Workers in Africa: A Perspective

    by Hillary Ngolobe, Jerom Okot, Daniel S. Ebbs, Kevin D. Dieckhaus, Felix Bongomin

    Infectious diseases remain a major global public health concern, disproportionately causing morbidity and mortality in low- and middle-income countries. Sexually Transmitted Infections (STIs) heavily affect sexually active populations. Sex workers, encompassing female sex workers (FSWs), male sex workers (MSWs), and transgender/gender-diverse individuals, face heightened vulnerabilities due to occupational exposures, structural barriers, stigma, and criminalization. While substantial focus has historically centered on HIV, non-HIV STIs such as Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and viral hepatitis present significant co-morbidity. Crucially, drug resistance across these pathogens presents distinct biological and epidemiological challenges: bacterial antimicrobial resistance (AMR) in N. gonorrhoeae and C. trachomatis, antiretroviral (ARV) resistance in HIV, and direct-acting antiviral (DAA) resistance in hepatitis B and C. This perspective article synthesizes the current epidemiological landscape, critiques the reliance on syndromic management over molecular diagnostics (e.g., NAATs, point-of-care, and genomic surveillance), highlights diagnostic stewardship, and outlines priority public health strategies aligned with the WHO 2022–2030 Global Health Sector Strategies.

  • Open Access

    Protective Effectiveness of Sars-Cov-2 Infection Risk Among Hybrid, Vaccine, and Infection-induced Immunity Against the Omicron Variant, K-Serosmart

    by Yifan Zhang, Won Chang, Kevin Dieckhaus, Suyoung Jo, Jina Han, Hye Jin Baek, Eunbi Noh, Kyuhyun Yoon, Jung Ae Kim, Jaehun Jung, et al.

    Background: Estimating infection risk from SARS-CoV-2 Omicron and post-Omicron sub-variants is challenging due to the high number of unconfirmed infections. We compared breakthrough infection risks among individuals with hybrid, vaccine-only, and infection-only immunity in South Korea, incorporating laboratory-confirmed and serology-inferred infections. Methods: Using nationwide surveillance data (August–December 2022), immunity was classified by vaccination history and spike (S) and nucleocapsid (N) antibody profiles. Outcomes were assessed using two definitions: conservative (laboratory-confirmed cases) and inclusive (serology-inferred infections identified by changes in N-antibody titers). Infection dates for unconfirmed events were imputed via predictive mean matching, enabling Kaplan–Meier analyses. Time-varying Cox models estimated log hazard ratios (log-HRs). Results: Including serology markedly increased four-month cumulative infection risk estimates: hybrid immunity rose from 2% to 20%, infection-only from 4% to 24%, and vaccine-only from 30% to 40%. With these additional infections, the relative advantage of hybrid immunity narrowed. Under the conservative definition, log-HRs declined for vaccine-only vs hybrid (4.10–2.34) and infection-only vs hybrid (1.56–0.31). Under the inclusive definition, the vaccine-only log-HR fell from 3.44 to 0.13, and the infection-only log-HR shifted from 3.31 to −0.56, indicating greater protection for infection-only immunity by month four. Conclusions: Because confirmed cases largely capture symptomatic disease, vaccination appears to provide added protection against severe outcomes, though this benefit wanes within months. The rapid decline of hybrid immunity and the large burden of unconfirmed infections highlight the need for routine serological surveillance to detect silent transmission and timely booster campaigns to mitigate severe disease during Omicron-driven waves.

  • Open Access

    SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

    by Kevin D. Dieckhaus, Min-Jung Kim, Jian-Bing Shen, Tina S. Liang, Michael J. Kleinberg, Kristen M. Siedlarz, David B. Banach, Mark L. Metersky, Rob P. Fuller, Eric M. Mortensen, et al.

    Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, however, neutralizing antibody responses subside with time and may be influenced by many variables. We sought to understand the dynamics between vaccine products, prior clinical illness from SARS-CoV-2, and incidence of vaccine-associated adverse reactions on antibody decay over time in HCWs at a university medical center. A cohort of 296 HCWs received standard two-dose vaccination with either bnt162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) and were evaluated after two, six, and nine months. Subjects were grouped by antibody decay curve into steep antibody decliners gentle decliners. Vaccination with mRNA-1273 led to more sustained antibody responses compared to bnt162b2. Subjects experiencing vaccine-associated symptoms were more likely to experience a more prolonged neutralizing antibody response. Subjects with clinical SARS-CoV-2 infection prior to vaccination were more likely to experience vaccination-associated symptoms after first vaccination and were more likely to have a more blunted antibody decay. Understanding factors associated with vaccine efficacy may assist clinicians in determining appropriate vaccine strategies in HCWs.


  • Open Access

    Modeling HIV Transmission from Sexually Active Alcohol-Consuming Men in ART Programs to Seronegative Wives

    by Kevin D. Dieckhaus, Toan H. Ha, Stephen L. Schensul, Avina Sarna

    Background: The rollout of antiviral therapy in Low and Middle Income Countries (LMICs) has reduced HIV transmission rates at the potential risk of resistant HIV transmission. We sought to predict the risk of wild type and antiviral resistance transmissions in these settings. Methods: A predictive model utilizing viral load, ART adherence, genital ulcer disease, condom use, and sexual event histories was developed to predict risks of HIV transmission to wives of 233 HIV+ men in 4 antiretroviral treatment centers in Maharashtra, India. Results: ARV Therapy predicted a 5.71-fold reduction in transmissions compared to a model of using condoms alone, with 79.9%, of remaining transmissions resulting in primary ART-resistance. Conclusions: ART programs reduce transmission of HIV to susceptible partners at a substantial increased risk for transmission of resistant virus. Enhanced vigilance in monitoring adherence, use of barrier protections, and viral load may reduce risks of resistant HIV transmissions in LMIC settings.


  • Open Access

    Human Brucellosis in Rural Uganda: Clinical Manifestations, Diagnosis, and Comorbidities at Kabale Regional Referral Hospital, Kabale, Uganda

    by Kevin D Dieckhaus, Peterson S Kyebambe

    Background: Brucellosis is a zoonotic infection transmitted to humans through direct contact with infected animals, their products, or excreta such as urine or dung. Brucellosis is associated with significant morbidity in Southwestern Uganda, where cattle and goat rearing are a major economic industry. As in many settings in sub-Saharan Africa, diagnosis and management of brucellosis remain a challenge due to the presence of comorbidities and limitations in resources for diagnostic testing and therapy. Methods: A chart review was conducted to characterize the clinical manifestations, diagnosis, comorbidities, and management of 101 patients treated for brucellosis at the Kabale Regional Referral Hospital from September 2002 to May 2010. Results: Patients presented with substantial comorbidities. The most common manifestation of illness was osteoarticular, but disease manifestations were quite varied. A high rate of focal illness in this cohort (77%) was observed. Conclusions: Clinicians in this setting should be cognizant of the varied presentations, comorbidities, and treatment options for this disease.


  • Classic viral exanthems

    by Lisa M. Chirch, Kevin D. Dieckhaus, Jane M. Grant-Kels